Insulin glargine , marketed by Sanofi-Aventis under the name Lantus , is a long-acting basal insulin analogue , usually given once or twice daily to help control the blood sugar level of those with diabetes . more

Insulin glargine , marketed by Sanofi-Aventis under the name Lantus , is a long-acting basal insulin analogue , usually given once or twice daily to help control the blood sugar level of those with diabetes . Its theoretical advantage is that it has a duration of action up to 24 hours, with a "less peaked" profile than NPH. Thus, it more closely resembles the basal insulin secretion of the normal pancreatic beta cells. In type 2 diabetes and in combination with a short acting sulfonylurea (drugs which stimulate the pancreas to make more insulin), it can offer moderate control of serum glucose levels. In the absence of endogenous insulin (Type 1 diabetes or depleted type 2), Lantus needs the support of a fast acting insulin taken with food to reduce the effect of prandially derived glucose. It is post-prandial glucose elevation which more significantly affects HbA 1c and thus determines the progression of the long-term complications of diabetes mellitus. less